Hypercholesterolemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Lipoprotein disorders are clinically significant due to their role in atherogenesis and the associated risk of atherosclerotic cardiovascular disease (ASCVD). In patients with established ASCVD (secondary prevention), cholesterol-lowering interventions consistently reduce cardiovascular mortality and events across genders and age groups. Lipoproteins, composed of lipids and proteins, transport cholesterol, triglycerides, and fat-soluble vitamins in plasma to various organs. High cholesterol is defined as LDL-cholesterol levels exceeding 190 mg/dL, greater than 160 mg/dL with one significant risk factor, or greater than 130 mg/dL with two cardiovascular risk factors. Key risk factors include age (≥45 years for males, ≥55 years for females), a positive family history of premature ASCVD (onset before 55 years in males and 65 years in females), hypertension, diabetes, smoking, and low HDL-cholesterol levels (<40 mg/dL in males and <55 mg/dL in females). Familial hypercholesterolemia involves defects or absence of the LDL receptor, impairing hepatic cholesterol uptake. The liver typically processes two-thirds of circulating LDL. Numerous mutations in the LDL receptor gene manifest as hypercholesterolemia. The cornerstone of hypercholesterolemia management includes a healthy lifestyle, maintaining optimal weight, smoking cessation, 150 minutes of weekly exercise, and a diet low in saturated and trans fats and rich in fiber, fruits, vegetables, and fatty fish. Plant stanols (2 g/day) can reduce LDL-C levels. Statins, the preferred drug class, lower LDL-C by 22% to 50% and reduce cardiovascular events in primary and secondary prevention trials. Significant side effects include elevated transaminases, myalgia, myopathy, and new-onset diabetes. If transaminases exceed three times the upper limit of normal, the statin dose should be reduced or switched. Myopathy, a severe complication, can lead to rhabdomyolysis and acute renal failure. The risk increases with certain drugs, including gemfibrozil, macrolide antibiotics, azole antifungals, protease inhibitors, cyclosporine, nefazodone, other CYP3A4 inhibitors, and multisystem diseases. Some patients may require additional drugs to achieve adequate LDL-C control despite high-dose statin therapy. Cholesterol absorption inhibitors (e.g., ezetimibe) and bile acid sequestrants are next-line therapies due to their safety in combination with statins. Niacin can further lower LDL-C in primary prevention but is not recommended for patients with ASCVD.
Thelansis’s “Hypercholesterolemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hypercholesterolemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Hypercholesterolemia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Hypercholesterolemia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment